Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

NNASDAQ:ELVN
47.62
USD
-1.18
(-2.42%)
-1.69EPS
3.37BMarket Cap
Mar 18Next Earn

Total Valuation

USD

As of September 30, 2026, Enliven Therapeutics, Inc. carries a market capitalization of 3.37B, placing it among publicly traded companies globally. Its enterprise value stands at 2.49B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.37B
Enterprise Value2.49B

Important Dates

Enliven Therapeutics, Inc.'s next confirmed earnings release is scheduled for March 18, 2027.

Earnings Date3/18/2027

Share Statistics

As of September 30, 2026, Enliven Therapeutics, Inc. has 73.56M shares outstanding.

Shares Outstanding73.56M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio3.85
P/TBV Ratio3.85
P/FCF Ratio-46.45
P/OCF Ratio-46.59

Financial Position

As of September 30, 2026, Enliven Therapeutics, Inc. maintains a current ratio of 45.95, meaning it holds 46.0x the short-term assets needed to cover near-term liabilities.

Current Ratio45.95
Quick Ratio45.41
Debt / Equity0.15
Debt / EBITDA-0.01

Financial Efficiency

Over the twelve months ended September 30, 2026, Enliven Therapeutics, Inc. posted a negative return on equity (ROE) of -16.77, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -16.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 60.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-16.77
Return on Assets (ROA)-16.35
Employee Count60.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Enliven Therapeutics, Inc.'s stock has gained approximately 115.77% over the past 52 weeks. The 50-day moving average sits at 46.20, while the 200-day moving average is 43.94.

52-Week Price Change115.77%
50-Day Moving Average46.20
200-Day Moving Average43.94

Income Statement

USD

Over the twelve months ended September 30, 2026, Enliven Therapeutics, Inc. generated - - in revenue and converted that into -113.48M in net income, yielding earnings per share of -1.69. EBITDA reached -135.28M, while operating income came in at -135.36M.

Operating Income-135.36M
Pretax Income-113.48M
Net Income-113.48M
EBITDA-135.28M
EBIT-135.36M
Earnings Per Share (EPS)-1.69

Balance Sheet

USD

As of September 30, 2026, Enliven Therapeutics, Inc. holds 884.35M in cash and equivalents against 1.32M in total debt, resulting in a net debt position of -151.67M. Total book value stands at 876.95M, with working capital of 875.28M providing operational flexibility.

Cash & Cash Equivalents884.35M
Total Debt1.32M
Net Debt-151.67M
Equity (Book Value)876.95M
Book Value Per Share11.92
Working Capital875.28M

Cash Flow

USD

Enliven Therapeutics, Inc. produced -66.21M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -193,000.00 in capital expenditures, free cash flow totaled -66.41M - equivalent to -0.99 per share.

Operating Cash Flow-66.21M
Capital Expenditures-193,000.00
Free Cash Flow-66.41M
FCF Per Share-0.99

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -2.15: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -14.13, meaning Enliven Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-14.13
FCF Yield-2.15

Stock Splits

Enliven Therapeutics, Inc.'s most recent stock split took place on February 24, 2023 with a 4:1 split ratio.

Last Split Date2/24/2023
Split Ratio4:1

Scores

As of September 30, 2026, Enliven Therapeutics, Inc. has an Altman Z-Score of 99.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score99.77